Five potential therapeutic agents as antidepressants: a brief review and future directions

2015 ◽  
Vol 15 (9) ◽  
pp. 1015-1029 ◽  
Author(s):  
Sheng-Min Wang ◽  
Changsu Han ◽  
Soo-Jung Lee ◽  
Ashwin A Patkar ◽  
Prakash S Masand ◽  
...  
Keyword(s):  
Therapeutic Agents ◽  
Future Directions

scholarly journals Aloe Genus Plants: From Farm to Food Applications and Phytopharmacotherapy

2018 ◽  
Vol 19 (9) ◽  
pp. 2843 ◽  
Author(s):  
Bahare Salehi ◽  
Sevil Albayrak ◽  
Hubert Antolak ◽  
Dorota Kręgiel ◽  
Ewelina Pawlikowska ◽  
...  
Keyword(s):  
Therapeutic Agents ◽  
Food Preservation ◽  
Future Directions ◽  
Health Treatment ◽  
Phytochemical Composition ◽  
Primary Health ◽  
Medicinal Use ◽  
Food Applications ◽  
Ethnobotanical Uses ◽  
Oral Therapeutic

Aloe genus plants, distributed in Old World, are widely known and have been used for centuries as topical and oral therapeutic agents due to their health, beauty, medicinal, and skin care properties. Among the well-investigated Aloe species are A. arborescens, A. barbadensis, A. ferox, and A. vera. Today, they account among the most economically important medicinal plants and are commonly used in primary health treatment, where they play a pivotal role in the treatment of various types of diseases via the modulation of biochemical and molecular pathways, besides being a rich source of valuable phytochemicals. In the present review, we summarized the recent advances in botany, phytochemical composition, ethnobotanical uses, food preservation, and the preclinical and clinical efficacy of Aloe plants. These data will be helpful to provide future directions for the industrial and medicinal use of Aloe plants.

The Insights and Perspectives of Nitric Oxide-mediated Biofilm Eradication

2021 ◽  
Vol 21 ◽  
Author(s):  
Mingke Yuan ◽  
Tao Sun ◽  
Jianbing Wu ◽  
Yue Fei ◽  
Yueqi Yang ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Pathogenic Bacteria ◽  
Drug Sensitivity ◽  
Antimicrobial Agents ◽  
Therapeutic Agents ◽  
Recurrent Infections ◽  
Future Directions ◽  
Drug Permeability ◽  
Cyclic Diguanosine Monophosphate ◽  
Diguanosine Monophosphate

: Biofilms are among the most important causes of nosocomial and recurrent infections as biofilms confer antibiotic resistance to pathogenic bacteria and protect them from the host’s immune system. Thus, it is imperative to investigate effective therapeutic agents to counteract biofilms. As an important signaling molecule, nitric oxide (NO) plays a crucial role in various biological and pathological processes. NO could disperse biofilm and restore the drug sensitivity by reducing intracellular cyclic-diguanosine monophosphate (c-di-GMP) levels. This review highlights recent advances on antibacterial and antibiofilm effects of NO when NO was co-administered with other antimicrobial agents. A significant improvement in drug permeability and biofilm cell targeting and reduced cytotoxicity could be attained with this strategy. In this review, we briefly lay out challenges and propose future directions in this appealing avenue of research on NO-based therapy for biofilm eradication.

scholarly journals Extracellular vesicles: a promising cell-free therapy for cartilage repair

2021 ◽  
Author(s):  
Rizka Musdalifah Amsar ◽  
Christofora Hanny Wijaya ◽  
Ika Dewi Ana ◽  
Atik Choirul Hidajah ◽  
Hari Basuki Notobroto ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Extracellular Vesicles ◽  
Treatment Option ◽  
Cartilage Repair ◽  
Therapeutic Agents ◽  
Bioactive Components ◽  
Regenerative Capacity ◽  
Future Directions ◽  
Cartilage Injuries ◽  
Delivery Strategies

Few effective therapies for cartilage repair have been found as cartilage has a low regenerative capacity. Extracellular vesicles (EVs), including exosomes, are produced by cells and contain bioactive components such as nucleic acids, proteins, lipids and other metabolites that have potential for treating cartilage injuries. Challenges like the difficulty in standardizing targeted therapy have prevented EVs from being used frequently as a treatment option. In this review we present current studies, mechanisms and delivery strategies of EVs. Additionally, we describe the challenges and future directions of EVs as therapeutic agents for cartilage repair.

SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions

2011 ◽  
Vol 39 (5) ◽  
pp. 1441-1446 ◽  
Author(s):  
Marie-Louise Zani ◽  
Annabelle Tanga ◽  
Ahlame Saidi ◽  
Hélène Serrano ◽  
Sandrine Dallet-Choisy ◽  
...  
Keyword(s):  
Serine Proteases ◽  
Lung Diseases ◽  
Therapeutic Potential ◽  
Therapeutic Agents ◽  
Cathepsin G ◽  
Chronic Obstructive ◽  
Inhaled Drugs ◽  
Future Directions ◽  
Obstructive Pulmonary Disease ◽  
Chronic Lung Diseases

It is now clear that NSPs (neutrophil serine proteases), including elastase, Pr3 (proteinase 3) and CatG (cathepsin G) are major pathogenic determinants in chronic inflammatory disorders of the lungs. Two unglycosylated natural protease inhibitors, SLPI (secretory leucocyte protease inhibitor) and elafin, and its precursor trappin-2 that are found in the lungs, have therapeutic potential for reducing the protease-induced inflammatory response. This review examines the multifaceted roles of SLPI and elafin/trappin-2 in the context of their possible use as inhaled drugs for treating chronic lung diseases such as CF (cystic fibrosis) and COPD (chronic obstructive pulmonary disease).

Summary of the Workshop on Future Directions in Discovery and Development of Therapeutic Agents for Opportunistic Infections Associated with AIDS

1991 ◽  
Vol 164 (2) ◽  
pp. 244-251 ◽  
Author(s):  
B. E. Laughon ◽  
H. S. Allaudeen ◽  
J. M. Becker ◽  
W. L. Current ◽  
J. Feinberg ◽  
...  
Keyword(s):  
Opportunistic Infections ◽  
Therapeutic Agents ◽  
Future Directions

scholarly journals Sharing data from MS clinical trials: Opportunities, challenges, and future directions

2015 ◽  
Vol 21 (11) ◽  
pp. 1365-1368 ◽  
Author(s):  
Timothy Coetzee
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Clinical Trial Data ◽  
Therapeutic Agents ◽  
Research Community ◽  
Trial Data ◽  
Fundamental Question ◽  
Future Directions ◽  
Phase Ii And Iii

The treatment of people affected by multiple sclerosis, particularly the relapsing forms of the disease, has been transformed by the availability of various therapeutic agents. This landmark progress is due to an enormous foundation of clinical research and, particularly, numerous phase II and III clinical trials. Although the research community has many reasons to take pride in this progress, a fundamental question remains about whether opportunities for additional research are being lost due to inadequate clinical trial data sharing.

scholarly journals Antibiotic resistance breakers: current approaches and future directions

2019 ◽  
Vol 43 (5) ◽  
pp. 490-516 ◽  
Author(s):  
Mark Laws ◽  
Ali Shaaban ◽  
Khondaker Miraz Rahman
Keyword(s):  
Antibiotic Resistance ◽  
Therapeutic Agents ◽  
Resistant Bacteria ◽  
Future Directions ◽  
Global Response ◽  
Antibiotic Resistant ◽  
Current State ◽  
Novel Approaches ◽  
Future Direction ◽  
Promising Avenue

ABSTRACTInfections of antibiotic-resistant pathogens pose an ever-increasing threat to mankind. The investigation of novel approaches for tackling the antimicrobial resistance crisis must be part of any global response to this problem if an untimely reversion to the pre-penicillin era of medicine is to be avoided. One such promising avenue of research involves so-called antibiotic resistance breakers (ARBs), capable of re-sensitising resistant bacteria to antibiotics. Although some ARBs have previously been employed in the clinical setting, such as the β-lactam inhibitors, we posit that the broader field of ARB research can yet yield a greater diversity of more effective therapeutic agents than have been previously achieved. This review introduces the area of ARB research, summarises the current state of ARB development with emphasis on the various major classes of ARBs currently being investigated and their modes of action, and offers a perspective on the future direction of the field.

scholarly journals Uricases as Therapeutic Agents to Treat Refractory Gout: Current States and Future Directions

2012 ◽  
Vol 73 (2) ◽  
pp. 66-72 ◽  
Author(s):  
Xiaolan Yang ◽  
Yonghua Yuan ◽  
Chang-Guo Zhan ◽  
Fei Liao
Keyword(s):  
Therapeutic Agents ◽  
Future Directions
Sign in / Sign up

Export Citation Format

Share Document